key: cord-1050909-bde5si5c
authors: Galán Sánchez, José Luis; San Nicasio, Catiana Silvente; Olivares, Mónica González; Martín, Claudia García; Madueño, Kevin Díez; Martín Díaz, María Ángeles; Tarjuelo, Diana Velázquez; Dobao, Pablo de la Cueva
title: Experience in patients with hidradenitis suppurativa and COVID-19 symptoms
date: 2020-06-27
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.986
sha: 0086f487d0a4787c2fc076e9161942f489ac0562
doc_id: 1050909
cord_uid: bde5si5c

nan

and would like to share our experience.

Coronavirus disease 2019 (COVID-19) is an illness caused by SARS-CoV-2, which has spread quickly across the globe. This disease has a variable severity spectrum. A subgroup of patients (especially elderly people and patients with underlying medical comorbidities) develop a severe form characterized by interstitial pneumonia, acute respiratory distress syndrome and septic shock. Hidradenitis suppurativa (HS) is a chronic and recurring pathology of the pilosebaceous follicle. It is usually associated with several comorbidities (obesity, smoking, diabetes mellitus, cardiovascular pathology...) which, at the same time, are risk factors for the development of severe forms of COVID-19. 1, 2 In order to assess the severity of COVID-19 in HS patients, we performed a review of the medical records of the 75 HS patients that were monitored in our center during the period from February 15 th to April 15 th of 2020.

The data were collected directly from the electronic medical record. Verification of data was made by telephone contact with the 75 HS patients.

Of the 75 HS patients, 12 received biological treatment, 30 were treated with non-biological systemic drugs and 33 underwent topical treatment. Eight of them presented highly suggestive data of coronavirus infection, including, at least, one of the following: symptoms of febrile acute respiratory infection, anosmia, ageusia and compatible analytical or radiographic changes. None of them were tested for diagnostic confirmation, since only those patients who required hospital admission were tested at our center during this time frame. We collected some data from these 8 patients which are shown in Table- 1. We must specify that, according to the protocol of our center, unilobar pneumonia was not considered a severe form of COVID-19.

Regarding treatment, we highlight that there does not seem to be an increased risk of severe COVID-19 infection in our 2 patients with biological treatment, but the sample size is too small for generalizability. In any case, following the evidence available to date, the current recommendation would be not to withdraw the biological treatment in HS patients who present with symptoms of COVID-19, as in other immunomediated skin pathologies such as psoriasis. 3, 4, 5 We are aware of the limitations of this study, including the low sample size, the absence of statistical analysis and the lack of serologies or molecular research to confirm the diagnosis of COVID-19 infection. However, the main interest of this work is that, in a population area of the southeast of Madrid very widely affected by the pandemic (with 2176 confirmed severe cases during this period), we observe that there have not been any severe cases within a series of 75 patients with HS, even when these pathologies share risk factors, regardless of the treatment they receive.

Exploring the risk of severe COVID-19 infection in hidradenitis suppurativa patients

Adalimumab for Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic: Safety Considerations

COVID-19 and psoriasis: Should we fear for patients treated with biologics

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience